You can buy or sell ALDR and other stocks, options, ETFs, and crypto commission-free!
Alder BioPharmaceuticals, Inc. Common Stock, also called Alder BioPharmaceuticals, is a clinical-stage biopharmaceutical company, which discovers, develops and commercializes various therapeutic antibodies. Read More Its product portfolio includes ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine; and Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA.
52 Week High
52 Week Low
Alder BioPharmaceuticals stock rockets on heavy volume after $1.95 billion buyout deal
Alder Alert: Johnson Fistel Investigates Proposed Sale of Alder BioPharmaceuticals, Inc.; Are Shareholders Getting a Fair Deal?
Expected Nov 4, After Hours